Enzomenib might be the most promising agent so far, on a cross-trial basis.

Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.

Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.

JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.

The group claims a seven-day vein-to-vein time is unique, and says why this matters.

And the company might one day follow Galapagos into decentralised manufacturing.

Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.

A CD22-directed Car that has had several owners will next year deliver its most important dataset.

First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.